Mucpharm

About:

Mucpharm is a clinical-stage biopharma company focused on the treatment of mucin-containing and secreting cancers.

Website: https://mucpharm.com

Top Investors: Herzberg Family Office

Description:

Clinical stage bio-pharma company focused on the treatment of mucin-containing and secreting cancers. Bromelain and acetylcysteine, BromAcâ„¢, is a patented combination drug developed by our team for mucinous cancers, where the drug affects glycosidic linkages and disulphide bonds in glycoproteins including mucinous tumours. Bromelain is an enzyme extracted from pineapple stem or fruit (ananas comosus) and it is made up of a number of enzymes (proteases, carbohydrases, phosphatases, peroxidases, etc.) that gives it unique enzymatic properties for the hydrolysis of glycosidic bonds in complex carbohydrates. As a therapeutic molecule, it is currently used as a mucolytic in combination with acetylcysteine with anticancer properties for the treatment of mucinous tumours. It combines synergistically with a variety of anticancer drugs.

Total Funding Amount:

$6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Kogarah, New South Wales, Australia

Founded Date:

2016-01-01

Contact Email:

info(AT)mucpharm.com

Founders:

David Morris, Myer Herszberg, Sarah Valle

Number of Employees:

11-50

Last Funding Date:

2020-07-20

IPO Status:

Private

Industries:

© 2025 bioDAO.ai